Table 1.
Patient characteristics during follow-up
| Baseline (n =36) | 1 month (n = 35) | 3 months (n = 34) | 6 months (n = 34) | 12 months (n = 34) | ANOVA, P | |
|---|---|---|---|---|---|---|
| Donor age (years) | 44.3 ± 13.0 | |||||
| Age at HTX (years) | 45.48 | |||||
| Reason for transplantation | ||||||
| Cardiomyopathy, n (%) | 19 (53) | |||||
| Ischaemic heart disease, n (%) | 12 (33) | |||||
| Other, n (%) | 5 (14) | |||||
| Gender mismatch, n (%) | 7 (19) | |||||
| Pre-HTX PVR (wood unit) | 1.8 ± 1.2 | |||||
| BMI | 25.2 ± 5.1 | |||||
| Weight, kg | 78.5 ± 19.8 | 77.3 ± 18.6 | 77.6 ± 19.6 | 80.3 ± 19.2 | 79.7 ± 23.2 | 0.0001* |
| Diabetes, n (%) | 6 (16.7) | 5 (14.3) | 6 (17.6) | 6 (17.6) | 6 (17.6) | 0.73 |
| Hypertension, n (%) | 21 (58.3) | 21 (60.0) | 23 (67.6) | 26 (76.5) | 25 (73.5) | <0.01* |
| Hypercholesterolaemia, n (%) | 32 (88.9) | 32 (91.4) | 31 (91.1) | 31 (91.1) | 30 (88.2) | 1.00 |
| Medication | ||||||
| Prednisolone, n (%) | 36 (100) | 35 (100) | 34 (100) | 33 (97.1) | 31 (91.1) | <0.05* |
| Cyclosporine, n (%) | 6 (16.7) | 6 (17.1) | 4 (11.8) | 6 (17.6) | 5 (14.7) | 0.62 |
| Tacrolimus, n (%) | 29 (80.6) | 28 (80.0) | 28 (82.4) | 28 (82.4) | 29 (85.3) | 0.84 |
| Mycophenolate, n (%) | 36 (100) | 35 (100) | 33 (97.1) | 32 (94.1) | 27 (81.8) | <0.001* |
| Everolimus, n (%) | 4 (11.1) | 4 (11.4) | 4 (11.8) | 7 (20.6) | 8 (23.5) | 0.23 |
| Statins, n (%) | 30 (83.3) | 30 (85.7) | 31 (91.2) | 31 (91.2) | 31 (91.2) | 0.71 |
| ACE/ATII inhibitor, n (%) | 6 (16.7) | 11 (31.4) | 18 (52.9) | 23 (67.6) | 25 (73.5) | <0.0001* |
| Furosemide or bumetanide, n (%) | 20 (55.6) | 19 (54.3) | 13 (38.2) | 8 (23.5) | 6 (17.6) | <0.0001* |
| Thiazide, n (%) | 3 (8.3) | 3 (8.6) | 4 (11.8) | 3 (8.8) | 3 (8.8) | 0.91 |
| Calcium channel blocker, n (%) | 11 (30.6) | 11 (31.4) | 9 (26.5) | 10 (29.4) | 11 (32.4) | 0.93 |
| Aspirin, n (%) | 6 (16.7) | 7 (20.0) | 8 (23.5) | 10 (29.4) | 11 (32.4) | <0.01* |
| Biochemistry | ||||||
| Creatinine, µmol/L | 218.3 ± 195.4 | 158.3 ± 121.9 | 118.8 ± 79.3 | 103.2 ± 42.3 | 105.8 ± 73.9 | <0.0001* |
| Haemoglobin, mmol/L | 6.6 ± 0.8 | 6.9 ± 0.8 | 7.1 ± 1.1 | 7.8 ± 0.9 | 8.0 ± 0.8 | <0.0001* |
| Total cholesterol, mmol/L | 4.2 ± 1.0 | 4.8 ± 1.1 | 4.9 ± 1.3 | 5.0 ± 1.5 | 4.9 ± 1.5 | <0.01* |
| s-tacrolimus, µg/L | 7.6 ± 3.2 | 9.9 ± 3.3 | 9.1 ± 3.2 | 8.0 ± 2.9 | 7.0 ± 2.2 | <0.01* |
| s-everolimus, µg/L | 2.4 ± 0.8 | 3.7 ± 1.6 | 7.3 ± 4.5 | 3.8 ± 0.9 | 4.6 ± 0.7 | 0.06 |
Data are presented as absolute number and present or mean ± standard deviation.
PVR, pulmonary vascular resistance; BMI, body mass index.
*P < 0.05.